Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.

By E. Shimizu, K. Hashimoto, Naoe Okamura, Kaori Koike, N. Komatsu, Chikara Kumakiri, M. Nakazato, H. Watanabe, N. Shinoda, Sin-ichi Okada and 1 more. Biological Psychiatry, 2003

1,174 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/e68bd815332ff3595a8d624b5347174ec32f96f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. T. Rantamäki
2. H. Schmidt
3. Keri Martinowich
4. R. Duman
5. Eero Castrén
6. B. Lu
7. V. Võikar
8. Bruce S. McEwen

In Pharmacology

1. Eero Castrén
2. H. Schmidt
3. R. Duman

Citations in the corpus

• Interaction between BDNF and Serotonin: Role in Mood Disorders (2008, background): “Decreased serum BDNF levels have been found in patients with mood disorder and those under inordinate amounts of stress or in depressed states (Licinio and Wong, 2002; Shimizu et al, 2003; Karege et al, 2005).”
• The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior (2007, background): “In addition to reduced expression of BDNF in the hippocampus, it is interesting to note that serum (Karege et al., 2002, 2005a; Shimizu et al., 2003; Gervasoni et al., 2005; Aydemir et al., 2006) and plasma (Lee et al.”
• Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011, background): “, and several antidepressant therapies — including serotonin reuptake inhibitors, tricyclic antidepressants and electroconvulsive shock — have been reported to normalize serum BDNF level”
• Role of neurotrophic factors in depression. (2007, background): “Interestingly, several studies have found decreased blood levels of BDNF in depressed patients and, again, antidepressant therapy appears to normalize this change [6,7]; however, the relevance of these findings to the action of BDNF in the brain remains to be established.”
• Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “, 2015); decreased cortical BDNF is associated with major depression in humans (Duman, 2004); and cortical BDNF normalizes with anti-depressant treatment (Sen et al., 2008; Shimizu et al., 2003).”